Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C. Joss RA, et al. Among authors: stahel r. Ann Oncol. 1995 Jan;6(1):41-8. doi: 10.1093/oxfordjournals.annonc.a059039. Ann Oncol. 1995. PMID: 7536028 Free article. Clinical Trial.
Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
Joss RA, Bürki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, Ludwig C, Siegenthaler P, Alberto P, Stahel R, et al. Joss RA, et al. Among authors: stahel r. Cancer. 1990 Jun 1;65(11):2426-34. doi: 10.1002/1097-0142(19900601)65:11<2426::aid-cncr2820651104>3.0.co;2-3. Cancer. 1990. PMID: 2159837 Clinical Trial.
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Ghielmini M, et al. Among authors: stahel r. Ann Oncol. 2005 Oct;16(10):1675-82. doi: 10.1093/annonc/mdi320. Epub 2005 Jul 19. Ann Oncol. 2005. PMID: 16030029 Free article. Clinical Trial.
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Thürlimann B, et al. Breast Cancer Res Treat. 2009 Jan;113(1):137-44. doi: 10.1007/s10549-008-9912-9. Epub 2008 Feb 8. Breast Cancer Res Treat. 2009. PMID: 18259856 Free PMC article. Clinical Trial.
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; International Breast Cancer Study Group. Colleoni M, et al. Ann Oncol. 2009 Aug;20(8):1344-51. doi: 10.1093/annonc/mdp024. Epub 2009 May 25. Ann Oncol. 2009. PMID: 19468030 Free PMC article. Clinical Trial.
439 results